申请人:Boehringer Ingelheim International GmbH
公开号:US20210380574A1
公开(公告)日:2021-12-09
The present invention encompasses compounds of formula (I)
wherein R
1a
, R
1b
, R
2a
, R
2b
, Z, R
3
to R
5
, A, p, U, V, W, L and E have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.